<DOC>
	<DOCNO>NCT01261351</DOCNO>
	<brief_summary>The primary purpose trial evaluate coagulation activator marker patient pre eclampsia compare control ( normal pregnancy ) correlate marker severity pathology .</brief_summary>
	<brief_title>Study Coagulation Activation Markers Pre Eclampsia</brief_title>
	<detailed_description>100 pre-eclamptic patient compare 200 control patient ( 100 control match gestational age inclusion 100 control match delivery mode ( section ) . Blood urine sample collect PE diagnosis , delivery post partum . Two ax consider : 1 . Thrombography , kinetic measurement thrombin generation , study coagulant profile accord Hemker 's method CAT System ( Calibrated Automated Thrombogram ) thromboelastogram ROTEM technique ( delocalized coagulation analyzer ) , parallel specific activation marker ( thrombin-antithrombin complex , fibrin monomer ) . 2 . The balance prostacyclin/thromboxane A2 use ELISA method urine sample genotype-phenotype correlation ( Polymorphism prostacyclin-synthetase 's promoter CYP8A1 ) .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Eclampsia</mesh_term>
	<criteria>18 year old diagnosis pre eclampsia multiple pregnancy less 18 year old</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Pre eclampsia</keyword>
	<keyword>Endogenous thrombin potential</keyword>
</DOC>